LISI ACHIEVED ONCE AGAIN EARNINGS GROWTH OBJECTIVES

LISI ACHIEVED ONCE AGAIN EARNINGS GROWTH OBJECTIVES Press release Belfrt, February 14, 2018 Earnings grwth: Revenue: 1.64 Bn, up 72 M (+4.6%) LISI Aerspace has crssed the 1 Bn revenue mark and LISI Autmtive that f 500 M; Cntributin f external grwth transactins cmpleted in the United States in 2016 (LISI MEDICAL Remmele) and 2017 (TERMAX) ffset an unfavrable dllar effect; Organic grwth: +3.6%; strng in the first half (+6.1%), mre limited in the secnd half f the year (+1.0%); Operating incme up by nearly 14 M (+8.9%) Cntributin up acrss all three divisins; Operating margin imprved by 0.4 pint t 10.4%; Net incme stabilized at a high level ( 108 M), despite a highly negative financial result (- 21.6 M) due t currency fluctuatins Free Cash Flw highly psitive despite an unfavrable currency impact (- 27.4 M) and a recrd level f capital expenditures; Net debt under cntrl after the acquisitin f TERMAX; Prpsed dividend: 0.48 per share; 2018 bjectives: imprvement in perfrmance and strategic curse maintained. February 14, 2018 - The LISI Bard f Directrs met under the chairmanship f Mr. Gilles Khler and reviewed the audited financial statements fr the perid ended December 31, 2017. They will be submitted fr apprval t the General Meeting n April 24, 2018. 12 mnths ending December 31, 2017 2016 Changes Key elements f the incme statement Revenue M 1,643.4 1,571.1 4.6% EBITDA M 256.2 237.1 8.0% EBITDA margin % 15.6 15.1 0.5 pt Operating result (EBIT) M 171.4 157.5 8.9% Operating margin % 10.4 10.0 0.4 pt Earnings attributable t hlders f cmpany equity M 108.0 107.0 0.9% Net earnings per share 2.04 2.02 1.0% Key elements f the cash flw statements Operating cash flw M 203.8 195.8 + 8.0 M Capital expenditure, net M -140.1-119.6 + 20.5 M Free Cash Flw* M 46.3 73.5-27.2 M Key elements f the financial structure Net debt M 300.2 218.2 + 82.0 M Rati f net debt t equity 33.4% 25.2% +8.2 pts * In this press release, Free Cash Flw refers t cash flw minus net industrial investments and changes in wrking capital requirements (WCR). 1

Revenue reached 1,643.4 M, an increase f 72.3 M (+4.6%), with rganic grwth f 3.6%. At 1,643.4 M, cnslidated revenue fr fiscal 2017 were up +4.6% and reflect the fllwing elements: a scpe effect f 21.7 M crrespnding t: a negative impact f - 13.4 M r 0.8% f cnslidated sales, reflecting the sale f Précimétal Fnderie de Précisin (Belgium) n February 2, 2017; the 22.8 M incremental cntributin, i.e. 1.4% f cnslidated sales, f LISI MEDICAL Remmele, which has been integrated since May 1, 2016; 12.3 M, r 0.75% f cnslidated sales, brught by the integratin within LISI AUTOMOTIVE f the US cmpany TERMAX, a leading designer and manufacturer f metal and plastic clipped fastening slutins fr car bdies, effective since Nvember 1, 2017; an adverse effect f - 10.2 M due t currency fluctuatins; 60.8 M generated by rganic grwth. M LISI Cnslidated f which LISI AEROSPACE f which LISI AUTOMOTIVE f which LISI MEDICAL Q1 444.3 277.6 128.9 37.9 Q2 417.4 258.3 123.7 35.6 Organic grwth H1 2017/H1 2016 +6.1% +7.4% +3.7% +7.1% Q3 369.7 222.6 116.2 31.1 Q4 412.0 242.4 137.3 32.5 Organic grwth H2 2017/H2 2016 +1.0% - 1.1% +9.6% -8.6% 2017 1,643.4 1,000.9 506.0 137.0 Expressed at a cnstant scpe and exchange rates, revenue are up +3.6% (+4.6% in 2016). Half-yearly analysis Organic grwth slwed dwn in the secnd half (+1.0%), particularly in the LISI AEROSPACE and LISI MEDICAL divisins after a sustained first half (+6.1%). The LISI AUTOMOTIVE divisin enjyed gd mmentum. Quarterly analysis Cmpared with the same perid last year, the furth quarter psted verall rganic grwth f +2.8%, mainly driven by the "Structural Cmpnents" segment in the aerspace industry and the entire LISI AUTOMOTIVE divisin. Aerspace "Fasteners" and the Medical Divisin shwed n sign f imprvement ver the furth quarter f the previus year. Divisinal analysis On a like-fr-like basis and restated fr the currency effect, LISI AEROSPACE's annual revenue grwth std at +3.3%. The decline f the divisin in the secnd half (-1.1%) cmpared t the first (+7.4%) is mainly attributable t the "Fasteners" activity in Eurpe: in fact, this has been negatively affected 2

nt nly by Airbus's destcking, but als by the acceleratin f the dllar depreciatin against the eur. In the United States, the "Fasteners" activity is picking up steam at Being, while the active repsitining f LISI AEROSPACE with the distributin sectr is hampered by the lw level f activity in business and reginal aircraft. The "Structural Cmpnents" shwed gd mmentum thrughut the year, thanks in particular t the cntinued ramp-up f the new prgrams, including the LEAP engine. Sales at the LISI AUTOMOTIVE divisin accelerated between the first and secnd half (+3.6% in H1, +14.4% in H2) in a Eurpean market that remained rbust. The increase in revenue is particularly nticeable in the "Clipped Slutins" and "Safety Mechanical Cmpnents" segments; it reflects the gains in market share and the ramping up f new prducts. Revenue thus reached the histrical level f 506.0 M, up +8.8% cmpared t 2016, with +6.5% rganic grwth supprted by a strng rder intake fr new prjects at mre than 10% f sales. The LISI MEDICAL divisin benefited frm the full year effect f the integratin f LISI MEDICAL Remmele (incremental sales revenue f 22.8 M ver the perid). At cnstant scpe and exchange rates, sales decreased by -2.3% with a secnd half-year shwing a net drp (-8.6%) cmpared with the first (+7.1%). LISI MEDICAL Remmele had t cpe with a temprary shift in the ramping up f sme f its prducts in the field f minimally invasive surgery and was als affected by the reassignment f tw significant prducts t ther prductin prcesses. Operating incme increased by 14 M, bringing the perating margin up t 10.4%, an imprvement f 0.4 pint. At 256.2 M, EBITDA rse by +8.0% (+ 19.1 M) and amunted t 15.6% f sales. The perating prfit (EBIT) increased by 13.9 M (+8.9%) t 171.4 M, despite an unfavrable currency effect f -5.3 M. The perating margin reached 10.4%. Up 0.4 pint frm 2016, it is in line with the Grup's bjectives, given the evlutin f its business mix. This perfrmance is attributable t an imprvement in the peratinal quality acrss the all Grup. The cntributin frm the prductivity gains f the LEAP prgram (LISI Excellence Achievement Prgram), the gradual rerientatin f the activities f the autmtive divisin twards prduct ranges that yield higher margins, as well as the effects f the capital expenditure prgram, have been decisive. In additin, and in accrdance with its cmmitments, the Grup halved the additinal csts generated in the phase f steep ramp-up f the new prgrams in the "Structural Cmpnents" segment. The psitive prductivity effects f rbtics and the reductin in the cst f launching new prducts and shuld als be nted. The year 2017 cnfirms the gradual rebalancing f the cntributin f the three divisins. All saw their perating prfit increase in value cmpared t the previus year. If the Aerspace Divisin remains the largest cntributr t the cnslidated perating incme (75% f the Grup; 78% in 2016), the Autmtive Divisin imprved its prfitability t 6.6%. The Medical Divisin psted perating incme up + 9.8 M, r 7.1% f sales. The strngly negative impact f the financial result (- 21.6 M), cmpared t 2016 (+ 13.3 M), is explained by the fllwing main factrs: the financial expenses, crrespnding t the cst f the lng-term net debt, amunted t - 5.9 M (- 5.1 M in 2016), i.e. an average fixed rate f 2.01% (1.70 % in 2016). This rate increase is ffset by gains generated n current cash investments (+ 2.7 M vs. + 0.8 M in 2016); the revaluatin f debts and receivables mainly denminated in dllars (- 32.4 M vs. + 17.5 M in 2016). Receivables and investments in freign currencies were mechanically affected by the sharp drp f this currency against the eur; the psitive impact f the valuatin f currency hedging instruments (+ 13.9 M vs. + 0.9 M in 2016). Nn-current csts weighed dwn the net result fr - 3.7 M (- 10.0 M in 2016) and mainly relate t cnsulting fees related t the relcatin f the Blgne site (Haute-Marne). 3

The tax expense, calculated n the basis f the crpratin tax as a percentage f net incme befre taxes, reflects an effective average rate f 26.8%, dwn frm 33.7% in 2016. Restated frm ne-ff items (rate change in France and the United States, additinal cntributin and censrship f the 3% dividend cntributin in France, transitin tax in the United States). The effective tax rate wuld be 31.1%. At 108.0 M, net incme exceeds that f 2016 ( 107.0 M). Per share, it amunts t 2.04 ( 2.02 in 2016). Based upn these results, the Grup will ask the Sharehlders' General Meeting t apprve setting the dividend at 0.48 per share fr the 2017 financial year. The gd level f prfitability achieved in 2017 largely financed the recrd amunt f capital expenditures while generating a highly psitive Free Cash Flw. Cash flw reached 203.8 M (+ 8.0 M, 12.4% f cnslidated sales, cmpared t 195.8 M in 2016). In a cntext f strng grwth, the Grup managed t reduce its inventry again: expressed in days f sales, it decreased by 7 days cmpared t the 2016 financial year, a gain f nearly tw weeks in tw years. Thrugh strict management discipline, custmer late payment rates have been reduced, lwering cnslidated wrking capital requirements t 74 days in 2017 (76 days in 2016). In line with previus years, LISI cntinued its capital expenditures in 2017 at sustained pace: up by mre than 20 M, capital expenditures represent 8.5% f sales and were mainly devted t: differentiating technical initiatives acrss the divisins (rbtizatin); initiating the last phase f the Villefranche-de-Ruergue prject; the peratinal start-up f the Frge 2020 prject (Blgne site); increase in the capacity dedicated t the manufacturing f new prducts. The Grup was nnetheless able t finance the capital expenditure prgrams while generating psitive Free Cash Flw f 46.3 M despite an unfavrable currency impact f - 27.4 M. LISI enters 2018 with a healthy financial structure In a 2017 fiscal year marked by an unprecedented amunt f investment, LISI has maintained a sund financial structure. Thus, the return n capital emplyed (befre tax) displays gd resistance: it std at 15.0% at the end f the year, cmpared with 15.5% as at December 31, 2016. The increase in net financial debt, which includes 100% f the acquisitin f TERMAX 1, was limited t 82.0 M and amunted t 300.2 M as at December 31, 2017. It represents 33.4% f sharehlders equity (25.2% in 2016 and 1.2 x EBITDA). LISI AEROSPACE The billin eur revenue mark is crssed fr the first time, with a strng disparity in rganic grwth between the first (+7.4%) and the secnd (-1.1%) half f the year; Imprvement f all the management indicatrs versus the prir year, with a sharp cntrast between the first and secnd half f the year, the latter being affected by the temprary adjustment f Airbus inventries and the adverse effect related t the decline f the dllar against the eur; Psitive Free Cash Flw after a sharp increase in capital expenditures (+11.0%); Challenging start t 2018 in line with the secnd half f 2017. 1 It shuld be recalled that the acquisitin f TERMAX was structured in tw stages: as a first step, the sharehlders f TERMAX Crpratin sld 51% f the capital t LISI AUTOMOTIVE fr apprximately 51 M. While the LISI Grup is expected t acquire the balance f the capital by 2020, it has decided t recgnize as f December 31, 2017 the entire crrespnding debt, i.e. apprximately 123 M. 4

Revenue (in M) 1,000.9 987.2 2017 2016 Change +3.3% On a cnstant scpe and exchange rate basis Operating prfit 128.1 122.9 +4.2% As a % f revenue 12.8% 12.4% +0.4 pt Free Cash Flw ( M) 61.6 32.3 + 29.3 M As a % f revenue 6.2% 3.3% +2.9 pts LISI AUTOMOTIVE Revenue exceeded 500 M fr the first time; New increase in rder intake fr new prducts and accelerated grwth in internatinal markets; 5 th cnsecutive year f imprvement in perating margin, reflecting the strategy f changing the prduct mix twards mre value-added prducts; psitive Free Cash Flw fr the secnd year in a rw, with significant imprvement cmpared t 2016; Gd visibility ver fiscal year 2018, driven by new prducts and by the full-year benefits frm TERMAX's cntributin. 2017 2016 Change Revenue (in M) 506.0 465.3 +6.5% On a cnstant scpe and exchange rate basis Operating prfit 33.3 26.3 +26.6% As a % f revenue 6.6% 5.7% +0.9 pt Free Cash Flw ( M) 13.1 7.9 + 5.2 M As a % f revenue 2.6% 1.7% +0.9 pt LISI MEDICAL The Divisin's perfrmance is impaired by a very unfavrable vlume effect in the secnd half at LISI MEDICAL Remmele as well as by an increase in medical care expenses; Increase in perating incme in value; Further grwth in Free Cash Flw with a dubling f investments cmpared t 2016; Cntinued drp in inventries reaching the histrically lw level f 61 days; Gradual ramp-up f new prjects expected in 2018. 5

2017 2016 Change Revenue (in M) 137.0 119.1-2.3% On a cnstant scpe and exchange rate basis Operating prfit 9.8 9.3 +5.7% As a % f revenue 7.1% 7.8% -0.7 pt Free Cash Flw ( M) 6.7 3.7 + 3.0 M As a % f revenue 4.9% 3.1% +1.8 pt OUTLOOK Challenges will abund in 2018: LISI AEROSPACE: the cmpletin f numerus challenging prjects, including the relcatin f the Plish site dedicated t the finishing f blades, the further reductin in the additinal csts f industrializatin, cmpliance with the delivery prgrams in the "Structural Cmpnents" segment, the adaptatin t a slwer activity in " Fasteners" in Eurpe with a significant impact expected fr the first part f the year; LISI AUTOMOTIVE: the industrial materializatin f new rders, the extensin f the Czech site specializing in the prductin f safety mechanical cmpnents, the "Delle f the Future" prject, the effective ability t pass higher raw materials csts int selling prices; LISI MEDICAL: back t verall grwth. The Grup is fully cmmitted t achieving a duble-digit current perating incme, a psitive Free Cash Flw and a grwth in value f its perating indicatrs, in a cntext f currency vlatility. The pursuit and deplyment f many structuring industrial prjects (rbtizatin and prductivity imprvement, innvatin), the launch f the first initiatives in the field f the digitizatin f prductin, all aim at prviding technlgical lead t cnslidate its [cmpetitive] differentiatin in a sustainable manner in well-riented markets ver time. Cntact Emmanuel Viellard Tel: +33 (0)3 84 57 00 77 Email: emmanuel.viellard@lisi-grup.cm Website: www.lisi-grup.cm The next annuncements will appear after clse f trading n Paris Eurnext Sharehlders' General Meeting: April 24, 2018 Q1 2018 financial infrmatin: April 25, 2018 H1 2018 results: July 25, 2018 Q3 2018 financial Infrmatin: Octber 24, 2018 The LISI share is listed n Eurnext, cmpartment A and belngs t the CAC AERO & DEF., CAC All Shares, CAC Industrials indices, under the ISIN cde: FR 0000050353. LISI is a wrldwide leading manufacturer f fasteners and assembly cmpnents fr the Aerspace, Autmtive, and medical implants industries. Reuters:GFII.PA Blmberg:FII FP 6

LISI Grup cnslidated balance sheet ASSETS (in '000) 31/12/2017 31/12/2016 LONG-TERM ASSETS Gdwill 321 377 300 426 Other intangible assets 30 177 23 822 Tangible assets 619 593 570 877 Lng-term financial assets 9 982 9 481 Deferred tax assets 8 568 19 075 Other lng-term assets 429 950 Ttal lng-term assets 990 126 924 631 SHORT-TERM ASSETS Inventries 337 099 338 986 Taxes Claim n the state 41 269 6 772 Trade and ther receivables 261 249 260 416 Cash and cash equivalents 197 576 141 719 Ttal shrt-term assets 837 193 747 894 TOTAL ASSETS 1 827 319 1 672 525 TOTAL EQUITY AND LIABILITIES (in '000) 31/12/2017 31/12/2016 SHAREHOLDERS' EQUITY Share capital 21 610 21 610 Additinal paid-in capital 72 584 72 584 Treasury shares (14 720) (14 610) Cnslidated reserves 688 882 659 375 Cnversin reserves 8 419 27 742 Other incme and expenses recrded directly as sharehlders' equity 5 261 (13 452) Prfit (lss) fr the perid 107 965 107 008 Ttal sharehlders' equity - Grup's share 890 001 860 258 Minrity interests 7 664 4 964 Ttal sharehlders' equity 897 665 865 222 LONG-TERM LIABILITIES Lng-term prvisins 64 995 70 474 Nn-current financial debts 317 757 253 856 Other lng-term liabilities 11 605 12 392 Deferred tax liabilities 40 747 33 376 Ttal lng-term liabilities 435 104 370 098 SHORT-TERM LIABILITIES Shrt-term prvisins 15 156 23 174 Shrt-term brrwings 1 179 973 106 037 Trade and ther accunts payable 297 109 304 492 Taxes due 2 312 3 503 Ttal shrt-term liabilities 494 550 437 206 TOTAL SHAREHOLDERS EQUITY AND LIABILITIES 1 827 319 1 672 525 1 Of which banking facilities 16 441 15 984

LISI Grup cnslidated incme (in '000) 31/12/2017 31/12/2016 Pre-tax sales 1 643 356 1 571 104 Changes in stck, finished prducts and prductin in prgress (884) (1 519) Ttal prductin 1 642 472 1 569 585 Other revenues (a) 26 661 23 777 Ttal perating revenues 1 669 133 1 593 362 Cnsumed gds (443 119) (414 436) Other purchases and external expenses (338 332) (325 957) Taxes and duties (b) (12 171) (11 353) Persnnel expenses (including temprary emplyees) (c) (619 333) (604 484) EBITDA 256 178 237 132 Depreciatin (90 132) (80 872) Net prvisins 5 352 1 200 EBIT 171 398 157 460 Nn-recurring perating expenses (7 329) (12 950) Nn-recurring perating revenues 3 649 2 974 Operating prfit 167 718 147 483 Financing expenses and revenue n cash (2 421) (4 420) Revenue frm cash 3 445 1 146 Financing expenses (5 866) (5 566) Other interest revenue and expenses (19 166) 17 770 Other financial items 60 852 55 409 Other interest expenses (80 018) (37 639) Taxes (f which CVAE (Tax n Cmpanies Added Value)) (b) (39 182) (54 443) Share f net incme f cmpanies accunted fr by the equity methd 0 0 Prfit (lss) fr the perid 106 951 106 390 attributable as cmpany sharehlders equity 107 965 107 008 Interest nt granting cntrl ver the cmpany (1 014) (619) Earnings per share (in ) 2,02 2,00 Diluted earnings per share (in ) 2,02 2,00

LISI Grup cnslidated cash flw table (in '000) 31/12/2017 31/12/2016 Operating activities Net earnings 106 951 106 390 Elim. f the incme f cmpanies accunted fr by the equity methd Eliminatin f net expenses nt affecting cash flws: - Depreciatin and nn-recurrent financial prvisins 89 819 81 232 - Changes in deferred taxes 10 335 6 059 - Incme n dispsals, prvisins fr liabilities and thers (1 932) 911 Grss cash flw margin 205 173 194 592 Net changes in prvisins prvided by r used fr current peratins (1 335) 1 213 Operating cash flw 203 838 195 805 Incme tax expense (revenue) 28 847 48 385 Eliminatin f net brrwing csts 5 686 5 782 Effect f changes in inventry n cash 67 2 504 Effect f changes in accunts receivable and accunts payable 17 973 (23 729) Net cash prvided by r used fr peratins befre tax 256 411 228 747 Taxes paid (64 298) (29 807) Cash prvided by r used fr peratins (A) 192 113 198 938 Investment activities Acquisitin f cnslidated cmpanies (51 014) (92 136) Cash acquired 2 409 (1 973) Acquisitin f tangible and intangible fixed assets (141 694) (132 609) Acquisitin f financial assets Change in granted lans and advances (722) (746) Investment subsidies received Dividends received Ttal cash used fr investment activities (191 021) (227 463) Divested cash (5 701) 36 Dispsal f cnslidated cmpanies 13 060 Dispsal f tangible and intangible fixed assets 1 548 12 995 Dispsal f financial assets Ttal cash frm dispsals 8 907 13 031 Cash prvided by r used fr investment activities (B) (182 114) (214 434) Financing activities Capital increase 1 920 32 Net dispsal (acquisitin) f treasury shares Dividends paid t sharehlders f the Grup (23 873) (20 629) Dividends paid t minrity interests f cnslidated cmpanies Ttal cash frm equity peratins (21 954) (20 598) Issue f lng-term lans 50 913 88 376 Issue f shrt-term lans 126 640 52 028 Repayment f lng-term lans 1 372 (35 309) Repayment f shrt-term lans (102 807) (45 143) Net interest expense paid (5 680) (5 782) Ttal cash frm peratins n lans and ther financial liabilities 70 439 54 171 Cash prvided by r used fr financing activities (C) 48 485 33 573 Effect f change in freign exchange rates (D) (2 976) (8 149) Effect f adjustments in treasury shares (D) * (110) (762) Changes in net cash (A+B+C+D) 55 398 9 166 Cash at January 1st (E) 125 736 116 569 Cash at year end (A+B+C+D+E) 181 134 125 735 Cash and cash equivalents 197 575 141 719 Shrt-term banking facilities (16 440) (15 984) Clsing cash psitin 181 135 125 735

Change in LISI Grup cnslidated sharehlders' equity (in '000) Share capital Capital-linked premiums Treasury shares Cnslidated reserves Cnversin reserves Other incme and expenses recrded directly as sharehlders' equity Prfit fr the perid, grup share Grup's share f sharehlders' equity Minrity interests Ttal sharehlders' equity Sharehlders' equity at January 1, 2016 21 610 72 584 (14 740) 603 092 30 598 (2 652) 81 764 792 257 1 189 793 445 Prfit (lss) fr the perid N (a) 107 008 107 008 (619) 106 389 Translatin differential (b) (2 856) (2 856) (18) (2 874) Payments in shares (c) 1 604 1 604 1 604 Capital increase 0 0 0 3 947 3 947 Restatements f treasury shares (d) 130 95 225 225 Restatements as per IAS19 (g) (3 519) (3 519) (3 519) Apprpriatin f N-1 earnings 81 764 (81 764) 0 0 Change in scpe 0 512 513 Dividends distributed (20 629) (20 629) 0 (20 629) Reclassificatin 0 0 Restatements f financial instruments (f) (8 980) (8 980) (48) (9 028) Varius (e) (4 852) (4 852) (4 852) Sharehlders' equity at December 31, 2016 21 610 72 584 (14 610) 660 979 27 742 (15 056) 107 008 860 258 4 964 865 222 including ttal revenues and expenses psted fr the perid (a) + (b) + ( c) + (d) + ( e) + (f) (2 856) (12 405) 107 008 91 747 (685) 91 063 Sharehlders' equity as at January 1, 2017 21 610 72 584-14 610 659 375 27 742-13 452 107 008 860 258 4 964 865 222 Prfit (lss) fr the perid N (a) 107 965 107 965 (1 014) 106 951 Translatin differential (b) (19 324) (19 324) 73 (19 251) Payments in shares (c) 2 075 2 075 2 075 Capital increase 0 0 0 2 000 2 000 Restatements f treasury shares (d) (110) 156 46 46 Restatements as per IAS19 (g) 369 369 369 Apprpriatin f N-1 earnings 107 008 (107 008) 0 0 Change in scpe (57 244) (57 244) 0 (57 244) Dividends distributed (23 872) (23 872) 0 (23 872) Reclassificatin 0 0 Restatements f financial instruments (f) 18 188 18 188 86 18 274 Varius (e) 1 540 1 540 1 556 3 096 Sharehlders' equity at December 31, 2017 21 610 72 584 (14 720) 688 882 8 419 5 261 107 965 890 001 7 664 897 665 including ttal revenues and expenses psted fr the perid (a) + (b) + ( c) + (d) + ( e) + (f) + (g) (19 324) 18 713 107 965 107 355 (855) 106 500